Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Endologix, Inc.
Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess
Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.
Takeda Adds To Its Celiac Pipeline With Innate-Discovered Antibodies
Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease
Finance Watch: Founder-Friendly Curie.Bio Launches With $520m To Seed, Support New Companies
Private Company Edition: Alexis Borisy and his Curie.Bio co-founders will invest $5m-$7m to help companies get to lead optimization within 12-18 months. Also, Feng Zhang-founded Aera launched with $193m, Hexagon Bio raised a $77.3m series B round and Halda emerged with $76m.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
- Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Cardiovascular Dynamics, Inc.
- Nellix, Inc.
- PQ Bypass, Inc.
- Radiance Medical Systems, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.